How to unify drug discovery and clinical data: Dassault Systèmes 3D UNIV+RSES

A unified AI-native platform connecting science, medicine and patients across the full drug lifecycle.

Life Sciences organizations face a structural problem: discovery, clinical development, manufacturing and patient outcomes operate as disconnected silos, slowing learning cycles and delaying therapies. CIOs and R&D leaders need a single, AI-native data and modeling backbone that connects regulatory, safety, quality, clinical and manufacturing information in one continuous feedback loop. Softprom is the official distributor of Dassault Systèmes.

What was announced

On October 28, 2026, Dassault Systèmes announced it has completed the acquisition of ArisGlobal for $1.8 billion in cash at closing, with up to $200 million in additional consideration tied to multi-year AI-related revenue milestones. The company is uniting its Life Sciences and Healthcare capabilities into one AI-native enterprise platform on 3D UNIV+RSES, connecting BIOVIA, MEDIDATA and ArisGlobal.

Dr. Ashwini Zenooz has been appointed Executive Vice President and CEO of the Life Sciences and Healthcare sector, reporting to Pascal Daloz. ArisGlobal continues to be led by Aman Wasan as CEO.

Today our Life Sciences portfolio comes together in 3D UNIV+RSES: one AI-native enterprise platform connecting the full drug lifecycle in a continuous cycle of discovery, learning and improvement

Why this matters

For CIOs, CDOs and heads of R&D IT in pharma and biotech, the combined platform reduces integration overhead between scientific modeling, clinical trial systems and regulatory/safety reporting. ArisGlobal already serves more than 200 clients, including half of the top 50 global biopharma companies, as a single source of truth for regulatory, safety, quality and medical affairs. MEDIDATA has supported 42,000 clinical trials and 13 million patients, while BIOVIA covers modeling and simulation in science.

Technical details

• Platform: 3D UNIV+RSES AI-native enterprise platform built on 3DEXPERIENCE
• Brands unified: BIOVIA (science modeling), MEDIDATA (clinical), ArisGlobal (regulatory, safety, quality, medical affairs)
• Deal value: $1.8B cash at closing plus up to $200M tied to AI revenue milestones
• Scope: discovery, clinical development, manufacturing, real-world patient outcomes
• Core approach: Virtual Twins combined with AI for actionable scientific context

FAQ

What is 3D UNIV+RSES for Life Sciences?

It is an AI-native enterprise platform that connects discovery, clinical development, manufacturing and patient outcomes in one continuous data and modeling cycle on 3DEXPERIENCE.

How does the ArisGlobal acquisition change Dassault Systèmes' portfolio?

ArisGlobal adds regulatory, safety, quality and medical affairs as a single source of truth, complementing BIOVIA (science) and MEDIDATA (clinical) under one Life Sciences and Healthcare sector.

Who leads the new Life Sciences and Healthcare sector?

Dr. Ashwini Zenooz, appointed EVP and CEO of the sector, leads MEDIDATA, BIOVIA and ArisGlobal, reporting to CEO Pascal Daloz.

Softprom and Dassault Systèmes

Softprom is the official distributor of Dassault Systèmes. Our team supports evaluation, licensing and deployment of the Life Sciences and Healthcare portfolio for pharma, biotech, medtech and diagnostics customers.

Prepared by the Softprom editorial team based on vendor materials (Softprom DistriFlow). Source: original article.